United States: What Are The Top Hatch-Waxman And BPCIA Developments For July 2018?

This month, we highlight significant developments from July 2018, including the FDA’s Biosimilar Action Plan for “reducing gaming of FDA requirements or other attempts to unfairly delay competition” and the much anticipated Federal Circuit decision on tribal sovereign immunity in inter partes review (IPR) proceedings.



FDA Advisory Committee Materials Qualify as 102(b) Prior Art

Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 07/13/18 (Fed. Cir. Nos. 2017-1671, 2017-1673, 2017-1674, 2017-1675, 2017-1676, 2017-1677, 2017-2075)

In this consolidated appeal from decisions invalidating as obvious certain claims in six IPRs, appellant argued that the PTAB erroneously found certain FDA advisory committee materials qualified as printed publication prior art. The Federal Circuit affirmed, holding that substantial evidence supported the PTAB’s finding. The advisory committee meeting at issue was announced in the Federal Register and was open to the public. The Federal Register notice also provided a link to an FDA website where background and other materials were posted more than two months before the critical date. The court declined to impose an “indexing” requirement for printed publications.

Failure to Prove Inherent Obviousness

Endo Pharmaceuticals Solutions, Inc. v. Custopharm Inc., 07/13/18 (Fed. Cir. No. 2017-1719)

The Federal Circuit affirmed the district court’s finding that the prior art did not render the claimed invention obvious under an inherent disclosure theory. The district court found, and the Federal Circuit agreed, that Custopharm failed to prove its case by clear and convincing evidence as to multiple elements. “[T]here was no evidence in the record that a skilled artisan could determine the nondisclosed vehicle formulation based on the reported pharmacokinetic performance profile, or that the nondisclosed vehicle formulation was necessarily a feature of the TU injection studied in the Articles.” The Federal Circuit also affirmed the rejection of Custopharm’s motivation to combine argument.

Tribal Sovereign Immunity Does Not Bar IPRs

Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., 07/20/18 (Fed. Cir. Nos. 2018-1638, 2018-1639, 2018-1640, 2018-1641, 2018-1642, 2018-1643)

The Federal Circuit affirmed the PTAB’s decision that tribal sovereign immunity did not bar IPRs against patents owned by the Saint Regis Mohawk tribe. Although IPRs are a “hybrid” proceeding, the court determined that IPRs are more akin to a traditional federal agency enforcement action than a civil lawsuit in which tribal immunity would typically apply. Under controlling Supreme Court precedent, sovereign immunity does not apply where the federal government, acting through an agency, engages in an investigative action or pursues an adjudicatory agency action. Emphasizing that the PTO Director has “complete discretion” to institute review of the challenged patent the Federal Circuit determined that IPRs are like proceedings begun by an agency based on information provided by a private party. In further distinguishing IPRs from civil litigation, the court also noted that the PTAB may continue its review of a patent even if the patent owner drops out or chooses not to participate in the proceeding. The court expressly declined to address state sovereign immunity.


$10 Million Exceptional Case Award

Regeneron Pharmaceuticals, Inc. v. Merus N.V., (D.N.J. Civ. No. 14-cv-1650 (KBF)) – subscription required

Having earlier found the case to be “exceptional,” ( for further information, please see our March update) in an opinion dated June 25, but released in July, the district court awarded $8,332,453.46 in attorneys’ fees, $465,390.34 in expert fees, and $1,717,100.69 in litigation expenses and costs, along with interest, to Merus.

$1.5 Million in Fees and Costs to Shire

Shire LLC v. Abhai, LLC, 07/011/18 (D. Mass Civil Action No. 15-13909-WGY) – subscription required

The district court had previously awarded sanctions for litigation misconduct based on the disclosure of corrected stability and dissolution data during trial and ordered Shire to submit a revised claim for fees and costs limited to 1) time wasted dealing with the inaccurate stability and dissolution data, 2) discovering the litigation misconduct, and 3) addressing the revised data ( for further information, please see our March update). Shire requested $2.335 million and Abhai requested a reduction of $1.336 million. The court reduced the request by $833,579.59, awarding Shire fees and costs of $1,501,455.32.

At-risk Launch Preliminarily Enjoined

Indivior Inc. v. Dr. Reddy’s Laboratories S.A., 07/13/18 (DNJ Civ. Nos. 17-7111;18-1775;18-5288 (KM) (CLW))

The district court granted Indivior’s motion for a preliminary injunction in the face of a potential at-risk launch. In a prior case, construction of the terms “dried” or “drying” in the parent patent resulted in a judgment of non-infringement. The claims of the patent in suit lacked that term and the district court rejected the attempt to import a drying limitation into the claim. The court therefore found that Indivior would likely succeed in defeating arguments of claim and issue preclusion. On July 18, the court denied a motion to stay pending appeal.

Antibiotic Not a Lead Compound for Coagulation Inhibition

Bayer Intellectual Property GmbH v. Aurobindo Pharma Ltd., 07/13/18 (D. Del. Civil Action No. 15-902) – subscription required

Following a bench trial in this Xarelto® ANDA litigation, the court found that the asserted claims were not invalid for obviousness. One skilled in the art would not have selected a compound that was the most advanced oxazolidinone antibiotic in clinical trials as an antibiotic as a lead compound for developing factor Xa inhibitors. Rather, the skilled artisan would have selected from seven attractive leads with factor Xa activity. Nor would he or she have made any of the asserted modifications to defendants’ lead compound to arrive at the claimed compound. The court also found that multiple secondary considerations supported the non-obviousness of the claimed compound.

“Ensnarement” Bars Janssen’s Doctrine of Equivalents Theory

Janssen Biotech, Inc. v. Celltrion Healthcare Co. Ltd., 7/30/18 (D. Mass. C.A. No. 17-11008-MLW)

The district court granted defendants’ motion for summary judgment of non-infringement of Janssen’s cell culture media patent. Janssen alleged that defendants’ process for making biosimilar infliximab infringes the ’083 patent under the doctrine of equivalents. The court disagreed, holding that the range of equivalents necessary to cover defendants’ cell culture media would also ensnare the prior art. “Undisputed and strong evidence compels the conclusion that a person of ordinary skill in the art (a ‘POSA’) would have had the ability and motivation to combine familiar ingredients from prior art cell culture media compositions in predictable concentrations to create what Janssen claims as its hypothetical invention. Moreover, the POSA would have predicted the combination’s successful results. Therefore, ensnarement bars Janssen from prevailing under the doctrine of equivalents.”


FDA Releases Biosimilar Action Plan; Solicits Stakeholder Input; Public Hearing on September 4th

On July 18, the FDA released its Biosimilar Action Plan, which focuses on “four key areas:” improving efficiency of the biosimilar and interchangeable product development and approval process; maximizing scientific and regulatory clarity; improving understanding of biosimilars among stakeholders; and “supporting market competition by reducing gaming of FDA requirements or other attempts to unfairly delay competition.” Regarding the last, the Action Plan promises that FDA will “take action, whenever necessary, to reduce gaming of current FDA requirements, and coordinate with the Federal Trade Commission to address anti-competitive behavior.” FDA further intends to “work with legislators, as needed, to close any loopholes that may effectively delay biosimilar competition beyond the exclusivity periods envisioned by Congress.” On July 25, the Federal Register published a notice of public hearing on September 4, 2018, “soliciting input from the public on how to facilitate greater availability of biosimilar and interchangeable products while retaining the balance between competition and innovation that Congress intended to achieve under the BPCI Act.” Read more from the FDA here and here.

FDA Commissioner to Form Working Group to Develop Focused Drug Importation Policy

On July 19, the FDA Commissioner announced the formation of a new working group to “develop focused drug importation policy options to address access challenges related to certain sole-source medicines with limited patient availability, but no blocking patents or exclusivities.” Read the FDA statement here.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions